Skip to main content
. Author manuscript; available in PMC: 2010 Jul 16.
Published in final edited form as: Obesity (Silver Spring). 2009 Apr 16;17(10):1821–1829. doi: 10.1038/oby.2009.107

Figure 2.

Figure 2

Rimonabant in Obesity (RIO) study: placebo-subtracted changes in atherogenic plasma lipoproteins. Data from the intent-to-treat population, last observation carried forward. From Pi-Sunyer et al. (78); Després et al. (79); Scheen et al. (80); Van Gaal et al. (81). HDL-C, high-density lipoprotein-cholesterol.